SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical study entitled 'Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer' at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the clinical results of the study entitled 'A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol' at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

ATLANTA, Ga. -- ContinuLink, a leader in Web-based home care software has announced that it has entered into a business development relationship with Cardiocom to provide a two way interface between Cardiocom's Omnivisor Pro software application and the Web-based ContinuLink application. Cardiocom is a developer, manufacturer and clinical service provider of award-winning telehealth solutions.

SUNRISE, Fla. -- This Mother's Day, Interim HealthCare Inc., the nation's largest and oldest franchise healthcare company, is recognizing moms across the country with unique Mother's Day e-cards. The e-cards allow users to share their favorite stories about their mothers and create a customized flower in her honor.

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled 'Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer' (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.

LAS VEGAS, Nev. -- Sher Institute for Reproductive Medicine (SIRM) is donating free In-Vitro Fertilization (IVF) treatments at upcoming fertility education seminars on May 11 and 12, in celebration of Mother's Day on May 9, 2010. The donated treatment cycles are part of the Sher Institute 'Giving Back' Program.

PARAMUS, N.J. -- Topcon Medical Systems announced today that the mobile version of its successful EyeRoute(R) Image Management Suite is now available as a dedicated iPhone application from the Apple(R) iTunes store in North America. First presented in October 2009 at the American Academy of Ophthalmology Meeting in San Francisco, EyeRoute Mobile sets the stage for connectivity on the go.

LONDON, U.K. -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

SAN JOSE, Calif. -- Tuberculosis (TB) is still a global and local threat. Hear the latest global, U.S., California, and local trends in TB, and recommendations from the experts. Breathe California is hosting a state-wide Media Call on Tuberculosis on Tuesday, March 23, 10:30 a.m. PDT. March 24th is World TB Day.